168 related articles for article (PubMed ID: 26596768)
1. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival.
Qian Z; Zhou T; Gurguis CI; Xu X; Wen Q; Lv J; Fang F; Hecker L; Cress AE; Natarajan V; Jacobson JR; Zhang DD; Garcia JG; Wang T
Sci Rep; 2015 Nov; 5():16889. PubMed ID: 26596768
[TBL] [Abstract][Full Text] [Related]
2. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
Liu Z; Deng M; Wu L; Zhang S
Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
[TBL] [Abstract][Full Text] [Related]
3. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival.
Sun Z; Wigle DA; Yang P
J Clin Oncol; 2008 Feb; 26(6):877-83. PubMed ID: 18281660
[TBL] [Abstract][Full Text] [Related]
4. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
[TBL] [Abstract][Full Text] [Related]
5. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
6. Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis.
Ko JH; Gu W; Lim I; Bang H; Ko EA; Zhou T
PLoS One; 2014; 9(1):e86569. PubMed ID: 24466154
[TBL] [Abstract][Full Text] [Related]
7. Increased NRF2 gene (NFE2L2) copy number correlates with mutations in lung squamous cell carcinomas.
Sasaki H; Shitara M; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Mol Med Rep; 2012 Aug; 6(2):391-4. PubMed ID: 22614957
[TBL] [Abstract][Full Text] [Related]
8. Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism-related genes.
Pio R; Agorreta J; Montuenga LM
J Thorac Cardiovasc Surg; 2015 Oct; 150(4):986-92.e1-11. PubMed ID: 26162308
[TBL] [Abstract][Full Text] [Related]
9. Pathway-based gene signatures predicting clinical outcome of lung adenocarcinoma.
Chang YH; Chen CM; Chen HY; Yang PC
Sci Rep; 2015 Jun; 5():10979. PubMed ID: 26042604
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
11. Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma.
Zhang J; Bing Z; Yan P; Tian J; Shi X; Wang Y; Yang K
J Gene Med; 2019 Aug; 21(8):e3105. PubMed ID: 31215090
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
Wang D; Hao T; Pan Y; Qian X; Zhou D
Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of small non-coding RNAs at the DLK1-DIO3 imprinted locus predicts lung cancer patient outcome.
Enfield KS; Martinez VD; Marshall EA; Stewart GL; Kung SH; Enterina JR; Lam WL
Oncotarget; 2016 Dec; 7(49):80957-80966. PubMed ID: 27829231
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
16. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets.
Yao J; Zhao Q; Yuan Y; Zhang L; Liu X; Yung WK; Weinstein JN
PLoS One; 2012; 7(9):e45894. PubMed ID: 23029298
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
19. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
[TBL] [Abstract][Full Text] [Related]
20. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma.
Song Q; Shang J; Yang Z; Zhang L; Zhang C; Chen J; Wu X
J Transl Med; 2019 Mar; 17(1):70. PubMed ID: 30832680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
